The influence of acute varenicline administration on smoking and eating behavior in humans

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 1, 2008, Pages 165-169

  Stoops, William W ^a   Vansickel, Andrea R ^a,b   Glaser, Paul E A ^a   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Eating; Humans; Methylphenidate; Smoking; Varenicline

Indexed keywords

METHYLPHENIDATE; PLACEBO; VARENICLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEHAVIOR CHANGE; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REINFORCEMENT; SMOKING CESSATION;

ADULT; BENZAZEPINES; CARBON MONOXIDE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; FEMALE; HUMANS; MALE; METHYLPHENIDATE; QUESTIONNAIRES; QUINOXALINES; SMOKING;

EID: 50349094783     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.07.001     Document Type: Article

References (24)

1. Benowitz N.L., Zevin S., and Jacob III P. Suppression of nicotine intake during ad libitum cigarette smoking by high dose transdermal nicotine. J Pharmacol Exp Ther 287 (1998) 958-962
2. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 (2005) 3474-3477
3. Cousins M.S., Stamat H.M., and de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology 157 (2001) 243-253
4. Dayton P.G., Read J.M., and Ong W. Physiological disposition of methylphenidate C14 in man. Fed Proc 29 (1970) 354
5. Faessel H.M., Smith B.J., Gibbs M.A., Gobey J.S., Clark D.J., and Burstein A.H. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 46 (2006) 991-998
6. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
7. Hatsukami D., Lexau B., Nelson D., Pentel P.R., Sofuoglu M., and Goldman A. Effects of cotinine on cigarette self-administration. Psychopharmacology 138 (1998) 184-189
8. Hatsukami D., Mooney M., Murphy S., LeSage M., Babb D., and Hecht S. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav 86 (2007) 132-139
9. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
10. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70 (2006) 801-805
11. McColl S.L., Burstein A.H., Reeves K.R., Billing Jr. C.B., Stolar M., and Sellers E.M. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 83 (2008) 607-614
12. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 (2006) 1561-1568
13. Oliveto A.H., Bickel W.K., Hughes J.R., Shea P.J., Higgins S.T., and Fenwick J.W. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 261 (1992) 885-894
14. Perkins K.A., Fonte C., Meeker J., White W., and Wilson A. The discriminative stimulus and reinforcing effects of nicotine in humans following nicotine pretreatment. Behav Pharmacol 12 (2001) 35-44
15. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., and Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28 (2007) 316-325
16. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
17. Rush C.R., Essman W.D., Simpson C.A., and Baker R.W. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 21 (2001) 273-286
18. Rush C.R., Stoops W.W., Hays L.R., Glaser P.E., and Hays L.S. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 306 (2003) 195-204
19. Rush C.R., Higgins S.T., Vansickel A.R., Stoops W.W., Lile J.A., and Glaser P.E. Methylphenidate increases cigarette smoking. Psychopharmacology 181 (2005) 781-789
20. Shahan T.A., Odum A.L., and Bickel W.K. Nicotine gum as a substitute for cigarettes: a behavioral economic analysis. Behav Pharmcol 11 (2000) 71-79
21. Stoops W.W., Glaser P.E., Fillmore M.T., and Rush C.R. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 18 (2004) 534-543
22. Stoops W.W., Lile J.A., Glaser P.E., and Rush C.R. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol 13 (2005) 56-64
23. Vansickel A.R., Stoops W.W., Glaser P.E., and Rush C.R. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology 193 (2007) 305-313
24. www.chantix.com Accessed 2 April 2008.